Next Article in Journal
Glucuronides Hydrolysis by Intestinal Microbial β-Glucuronidases (GUS) Is Affected by Sampling, Enzyme Preparation, Buffer pH, and Species
Next Article in Special Issue
Fluorescently Labeled PLGA Nanoparticles for Visualization In Vitro and In Vivo: The Importance of Dye Properties
Previous Article in Journal
A Review on Recent Advancement on Age-Related Hearing Loss: The Applications of Nanotechnology, Drug Pharmacology, and Biotechnology
Previous Article in Special Issue
PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP
Review

PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases

1
Université de Bordeaux, INSERM U1212, CNRS UMR 5320, ARNA, ARN: Régulations Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, F-33076 Bordeaux, France
2
Univ. Bordeaux, CNRS, IMN, UMR 5293, F-33000 Bordeaux, France
*
Authors to whom correspondence should be addressed.
Academic Editor: Oya Tagit
Pharmaceutics 2021, 13(7), 1042; https://doi.org/10.3390/pharmaceutics13071042
Received: 3 June 2021 / Revised: 5 July 2021 / Accepted: 6 July 2021 / Published: 8 July 2021
Treatment of neurodegenerative diseases has become one of the most challenging topics of the last decades due to their prevalence and increasing societal cost. The crucial point of the non-invasive therapeutic strategy for neurological disorder treatment relies on the drugs’ passage through the blood-brain barrier (BBB). Indeed, this biological barrier is involved in cerebral vascular homeostasis by its tight junctions, for example. One way to overcome this limit and deliver neuroprotective substances in the brain relies on nanotechnology-based approaches. Poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) are biocompatible, non-toxic, and provide many benefits, including improved drug solubility, protection against enzymatic digestion, increased targeting efficiency, and enhanced cellular internalization. This review will present an overview of the latest findings and advances in the PLGA NP-based approach for neuroprotective drug delivery in the case of neurodegenerative disease treatment (i.e., Alzheimer’s, Parkinson’s, Huntington’s diseases, Amyotrophic Lateral, and Multiple Sclerosis). View Full-Text
Keywords: PLGA nanoparticles; neurodegenerative diseases; drug delivery; central nervous system; neuroprotective drugs PLGA nanoparticles; neurodegenerative diseases; drug delivery; central nervous system; neuroprotective drugs
Show Figures

Figure 1

MDPI and ACS Style

Cunha, A.; Gaubert, A.; Latxague, L.; Dehay, B. PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases. Pharmaceutics 2021, 13, 1042. https://doi.org/10.3390/pharmaceutics13071042

AMA Style

Cunha A, Gaubert A, Latxague L, Dehay B. PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases. Pharmaceutics. 2021; 13(7):1042. https://doi.org/10.3390/pharmaceutics13071042

Chicago/Turabian Style

Cunha, Anthony, Alexandra Gaubert, Laurent Latxague, and Benjamin Dehay. 2021. "PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases" Pharmaceutics 13, no. 7: 1042. https://doi.org/10.3390/pharmaceutics13071042

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop